stockrow
Saturday 7 November 2026
Export ALLO’s income statement to Excel — free account
Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023.
- Revenue
- +20,990.9%
- EPS
- +43.5%
- Free cash flow
- +17.7%
Quarter to June 2026, against a year earlier
1.04
0.05
−4.59%
Follow ALLO
Alert me
Allogene Therapeutics, Inc. (ALLO) P/E ratio
Allogene Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| 10 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ZURA Zura Bio Limited compare | n/m |
| EDIT Editas Medicine, Inc. compare | n/m |
| ALT Altimmune, Inc. compare | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| ALLO Allogene Therapeutics, Inc. | n/m |
| CCCC C4 Therapeutics, Inc. compare | n/m |
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| LYEL Lyell Immunopharma, Inc. compare | n/m |
| TRXB TRex Bio Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)